Core Points - Quantum BioPharma Ltd. has announced a public whistleblower policy offering rewards up to USD $7 million for information leading to a trial victory or settlement in its ongoing lawsuit against major financial institutions for stock manipulation [1][3][9] - The lawsuit seeks over USD $700 million in damages due to alleged illegal tactics, including "spoofing," which artificially depressed the company's stock price from approximately USD $460 in early 2020 to less than USD $10 by late 2024 [10][9] - The company emphasizes its commitment to restoring market integrity and holding alleged perpetrators accountable through this initiative [5][12] Whistleblower Policy - The cash reward will be granted if the information significantly contributes to a final judgment or binding settlement [3][4] - Eligible information includes evidence of illegal trading practices, such as spoofing and spreading false information [3][4] - The program does not interfere with existing SEC whistleblower programs, allowing individuals to report directly to the SEC while also participating in Quantum's initiative [6][7] Legal Context - The lawsuit is characterized as one of the largest spoofing cases in decades, with substantial evidence gathered by experienced law firms [10][12] - The company is actively seeking additional evidence and information from individuals who may have knowledge of the alleged manipulation [13][11] - Legal representation is provided on a contingency basis, meaning the company incurs no upfront legal costs [10] Company Overview - Quantum BioPharma focuses on developing innovative biopharmaceutical solutions for neurodegenerative and metabolic disorders [14] - The company retains a 20.10% ownership stake in Unbuzzd Wellness Inc., with a royalty agreement that could yield significant future revenues [14] - The company is committed to involving its shareholder community in addressing the impacts of stock manipulation [13]